HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

bendamustine

Subscribe to New Research on bendamustine

Also Known As:

Cytostasan; IMET 3393; Ribomustin; Treanda; Zimet 3393; bendamustin; bendamustine hydrochloride; ribosepharm brand of bendamustine hydrochloride; gamma-(1-methyl-5-bis(beta-chloroethyl)aminobenzimidazole)-(2)-butyric acid

Networked: 387 relevant articles (71 outcomes, 117 trials/studies)

Relationship Network

Drug Context: Research Results

Organic Chemicals: 58
- Hydrocarbons: 412
  - Halogenated Hydrocarbons: 31
    - Mustard Compounds: 2
      - Nitrogen Mustard Compounds: 1
        bendamustine: 387

Experts

1.	Cheson, Bruce D: 19 articles (05/2015 - 08/2002)
2.	Friedberg, Jonathan W: 9 articles (05/2015 - 01/2008)
3.	Pönisch, Wolfram: 9 articles (03/2015 - 08/2002)
4.	Niederwieser, Dietger: 8 articles (11/2015 - 08/2002)
5.	Ogura, Michinori: 8 articles (02/2015 - 09/2010)
6.	Rummel, Mathias J: 8 articles (04/2013 - 08/2002)
7.	Schwarzer, Andreas: 7 articles (11/2015 - 10/2008)
8.	Montillo, Marco: 7 articles (11/2014 - 09/2009)
9.	Kahl, Brad S: 7 articles (05/2014 - 01/2010)
10.	Weide, Rudolf: 7 articles (08/2013 - 02/2002)

Related Diseases

1.	Lymphoma (Lymphomas) 02/15/2015 - "We conclude that the high efficacy of bendamustine in treating CLL might be partly contributed to the expression of OAT3 in lymphoma cells and the high affinity of bendamustine for this transporter. " 01/01/2009 - "Overall, bendamustine has demonstrated promising results as therapy for non-Hodgkin's lymphomas and should be included in the armamentarium of agents used to treat relapsed indolent non-Hodgkin's lymphomas and may prove valuable as initial therapy for these diseases. " 08/01/2002 - "Bendamustine as a single agent is effective against aggressive lymphoma, even in cases of refractory disease. " 09/01/2010 - "Bendamustine is a unique cytotoxic agent that has demonstrated efficacy in the treatment of indolent B-cell non-Hodgkin lymphomas (B-NHLs). " 07/01/2014 - "Widely used in Eastern Europe for lymphoma and myeloma therapy during the 1970s and 1980s, bendamustine was not studied in well-designed clinical trials until the 2000s. "
2.	Non-Hodgkin Lymphoma (Lymphosarcoma) 08/01/2002 - "Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma." 05/01/2014 - "Bendamustine-based therapy as first-line treatment for non-Hodgkin lymphoma." 05/01/2014 - "The results of randomised and observational studies with bendamustine as front-line therapy in non-Hodgkin lymphoma (NHL) with emphasis on efficacy and toxicity are presented. " 03/01/2012 - "In indolent non-Hodgkin's lymphoma, assessment of bendamustine is mainly based on a single uncontrolled trial. " 11/14/2015 - "[Progress of bendamustine in the treatment of B cell non-Hodgkin lymphoma]."
3.	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 11/01/2013 - "Bendamustine proved to be effective for the treatment of chronic lymphocytic leukemia (CLL). " 11/01/2009 - "Bendamustine: a new treatment option for chronic lymphocytic leukemia." 10/01/2005 - "Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group." 09/01/2015 - "Routine Use of Bendamustine in Patients with Chronic Lymphocytic Leukemia: An Observational Study." 01/01/2001 - "In an open phase-II study we treated 23 patients with a median age of 62 years at study entry (43-86 years) with advanced, refractory or relapsed (Rai stage III n = 9, Rai stage IV n = 14) chronic lymphocytic leukemia (CLL) with bendamustine. "
4.	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 12/01/2015 - "Bendamustine is effective in B-cell malignancies, including mantle cell lymphoma (MCL), alone and in combination with other agents. " 07/01/2015 - "This study was a postapproval commitment to investigate bendamustine's effect on cardiac repolarization in treatment-naïve adults with advanced indolent NHL/mantle cell lymphoma (MCL). " 09/01/2010 - "In this multicenter phase II trial, the efficacy and safety of bendamustine were evaluated in Japanese patients with relapsed or refractory indolent B-NHL or mantle-cell lymphoma (MCL). " 12/01/2015 - "Synergistic Cytotoxicity of Bendamustine and the BTK Inhibitor in a Mantle Cell Lymphoma Cell Line." 09/01/2014 - "Bendamustine as salvage treatment for patients with relapsed or refractory mantle cell lymphoma patients: a retrospective study of the Spanish experience."
5.	Multiple Myeloma 10/01/2013 - "Proteomic studies of multiple myeloma in RPMI8226 cell line treated with bendamustine." 01/29/2010 - "Therefore, the role of bendamustine in patients with multiple myeloma should be investigated in further clinical trials." 12/01/2015 - "Bendamustine in heavily pre-treated patients with relapsed or refractory multiple myeloma." 11/01/2015 - "Bendamustine in multiple myeloma." 05/01/2015 - "Bendamustine in relapsed/refractory multiple myeloma: the "real-life" side of the moon."

Related Drugs and Biologics

1.	rituximab (Mabthera)
2.	Cyclophosphamide (Cytoxan)
3.	fludarabine
4.	Prednisone (Sone)
5.	Vincristine (Oncovin)
6.	Doxorubicin (Adriamycin)
7.	Melphalan (Alkeran)
8.	Mitoxantrone (Novantrone)
9.	Methotrexate (Mexate)
10.	Fluorouracil (Carac)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Combination Drug Therapy (Combination Chemotherapy)
3.	Stem Cell Transplantation
4.	Salvage Therapy
5.	Heterologous Transplantation (Xenotransplantation)